[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Bern\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":673},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,45,70,93,121,145,172,192,219,250,278,320,343,366,392,425,447,476,495,519,548,575,596,626,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100593995","prf-as-adjunct-to-subgingival-instrumentation-in-step-2-periodontal-therapy-100593995",false,"NCT07013682","PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy","Platelet Rich Fibrin Adjunctive to Non-surgical Periodontal Therapy: a 6-month Split-mouth Randomized Controlled Clinical Trial","PRFSTEP2","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Periodontitis stage II-IV, grade A\u002FB\u002FC, generalized\n* Presence of at least 20 teeth (excluding wisdom teeth)\n* Absence of removable dentures\n* Patients willing to provide written informed consent and to complete the 6- month study follow-up\n\nExclusion Criteria:\n\n* Patients already participating in other clinical trials\n* Periodontal treatment in the previous 12 months\n* Antibiotic treatment 3 months prior to study entry\n* Antibiotic prophylaxis required for dental treatment\n* Current use of any medication that may affect the clinical features of periodontitis\n* Pregnant\u002Flactating\n* Any condition that prevents venipuncture\n* Not willing to venous puncture\n* Current cancer treatment\n* History of radiation in the head-neck area",true,"ALL","18 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","Periodontitis is characterized by a chronic, multifactorial inflammatory process driven by dysbiotic plaque biofilms. It is recognized as the most common chronic inflammatory non-communicable disease in humans. The advanced and severe forms of periodontitis have an estimated prevalence of 7.4%, while milder forms can affect up to 50% of the population.\n\nIf left untreated, periodontitis can lead to tooth loss. However, it is largely preventable and treatable with mechanical non-surgical periodontal therapy. To improve periodontal healing and thus clinical attachment gain after non-surgical therapy, adjunctive bioactive formulations such as enamel matrix derivatives, sodium hypochlorite, locally delivered antimicrobials, or hyaluronic acid have recently been proposed. However, these agents are non-autologous formulations and expensive.\n\nPlatelet-rich fibrin (PRF) acts as a scaffold that inhibits the early migration of epithelial cells into the periodontal tissues. Its regenerative properties are primarily due to its ability to promote angiogenesis. This ability is attributed to the 3D fibrin matrix, which can simultaneously transport several cytokines and growth factors. These include vascular endothelial growth factor (VEGF), insulin growth factor (IGF), transforming growth factor β1 (TGF-β1) and platelet-derived growth factor (PDGF). PRF further shows antibacterial properties and accelerates soft tissue healing. So far PRF is not routinely used in periodontal non-surgical therapy.\n\nThe aim of this 6-month, split-mouth randomized clinical trial including 20 patients is to test whether PRF can improve the results after non-surgical therapy.",[29,30,31],"Periodontitis","Periodontal Inflammation","Periodontal Attachment Loss","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2025-05-01",{"date":40,"type":23},"2027-12-24",{"name":42,"class":43},"University of Bern","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100599657","early-feasibility-evaluation-of-the-unibe-hybrid-closed-loop-insulin-delivery-system-in-type-1-diabetes-ubloop-genesis-100599657","NCT07087340","Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop-Genesis","Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop - Genesis","UBLoop-Gen","Inclusion Criteria:\n\n* T1D diagnosis for at least one year.\n* Aged between 18 and 65 years old (inclusive).\n* Currently using insulin for at least six months.\n* Currently using closed-loop insulin therapy for at least three months.\n* Willingness to suspend any personal CGM for the duration of the pilot study once the study CGM is in place.\n* Willingness not to start any new non-insulin glucose-lowering agent during the study (including metformin\u002Fbiguanides, incretin agonists \\[GIP\u002FGLP-1RAs or GLP-1RAs\\], pramlintide, DPP-4 inhibitors, sulfonylureas, Sodium-glucose cotransporter-2 inhibitors \\[SGLT2 inhibitors\\], and nutraceuticals).\n* Understanding and willingness to follow the protocol and signed informed consent.\n\nExclusion Criteria:\n\n* An HbA1C ≥10% .\n* History of diabetic ketoacidosis (DKA) in the past 12 months.\n* History of severe hypoglycaemic event (Level 3): defined as seizure or loss of consciousness in the past 12 months.\n* Current uncontrolled chronic diabetic microvascular complications (neuropathy, retinopathy, renal diabetes disease, and diabetic gastroparesis).\n* Body Mass Index (BMI) ≤18.5 or ≥ 35 kg m2\n* Estimated glomerular filtration rate (eGFR) lab value below 30 mL\u002Fmin\u002F1.73 m2\n* Pregnancy or intent to become pregnant during the study.\n* Currently breastfeeding or planning to breastfeed.\n* Currently uncontrolled seizure disorder.\n* Planned surgery during the study duration.\n* Have uncontrolled hypertension (systolic BP above or equal to 160 mmHg and\u002For diastolic BP above or equal to 100 mmHg). If a participant is on anti-hypertensive therapies, doses must be stable for 30 days before screening. For participants with uncontrolled hypertension at the screening visit, antihypertensive medication may be started or adjusted.\\*\n* Personal history of one of the following cardiovascular conditions: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF) in the last three months before the screening.\n* Conditions that may increase the risk of induced hypoglycemia such as known coronary artery disease, CHF (Have NYHA Functional Classification III or IV CHF), history of any cardiac disorder or arrhythmia, history of cerebrovascular event, hypoglycemia-induced migraine within the past six months, seizure disorder, syncope, adrenal insufficiency, or neurological disease).\n* Cystic fibrosis.\n* Uncontrolled thyroid disease as judged by the investigator.\n* Have an uncontrolled psychiatric condition such as (major depressive disorder, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder, alcohol or drug abuse).\n* Treatment with a non-insulin glucose-lowering agent, except metformin, in stable doses in the last three months.\n* Participants receiving or have received systemic glucocorticoid therapy within three months before screening (Prednisolone 10mg daily or equivalent \\>2 weeks) or chronic systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, single intraarticular injection, or inhaled preparations).\n* Have current treatment with (or history of, within 3 months before screening) medications that may affect glucose metabolism, as judged by the investigator.\n* Current enrolment in another clinical trial, unless approved by the investigator of both studies, and if the clinical trial is a non-interventional registry trial.\n* Have evidence of a significant active, uncontrolled medical condition or a history of any medical problem capable of constituting a risk when using the study devices or interfering with the interpretation of data, as judged by the study physician at screening.","65 Years",{"count":55,"type":23},6,[26],"The study is investigating the early feasibility of a novel algorithm for a hybrid closed-loop (HCL) insulin delivery system in adult patients with Type 1 diabetes.\n\nParticipants will attend a study visit where the UBLoop system on a smartphone will manage insulin delivery via an insulin pump, using blood glucose values from a continuous glucose meter. Specialized staff and a remote monitoring system, which is integrated into the UBLoop system, will oversee the participants.",[59],"Type-1-Diabetes",[61,62],"Automated insulin delivery","Artificial pancreas","2026-06-29",{"date":33,"type":36},{"date":66,"type":36},"2026-01-21",{"date":68,"type":23},"2026-08-31",{"name":42,"class":43},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":19,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100387000","effect-of-placing-the-implant-crown-on-the-implant-on-the-same-day-as-the-implant-vs-4-weeks-later-100387000","NCT04319042","Effect of Placing the Implant Crown on the Implant on the Same Day as the Implant vs. 4 Weeks Later.","Influence of the Implant Loading Protocol on Implant Survival in Early Placed Single-tooth Implants in Mandibular First Molar Sites Using Computer-assisted Implant Surgery: A Randomized Clinical Trial (RCT).","Inclusion Criteria:\n\n* Age ≥ 20 years\n* Willingness to sign informed consent and to participate in the study\n* Plaque index according to Silness and Loe of \\\u003C 35% \\[26\\]\n* Presence of a mandibular first molar that has to be extracted\n* Sufficient vertical interocclusal space for the placement of an implant crown (7 mm)\n* Presence of an opposing natural or artificial tooth\n* Ridge height sufficient for the placement of a ≥ 10 mm-long implant\n* Sufficient ridge width for the placement of a 4.1mm diameter implant\n\nExclusion Criteria:\n\n* Any physical or mental disorder that would interfere with the ability to perform adequate oral hygiene or the capability of providing written informed consent and compliance to the protocol\n* Any disorder that would interfere with wound healing or represent a contraindication for implant surgery such as, but not limited to, uncontrolled diabetes or conditions resulting in or requiring immunosuppression, radiation, chemotherapy, frequent use of antibiotics or antiresorptive medication such as bisphosphonates\n* Pregnancy or lactation\n* Intention to become pregnant between inclusion and implant loading\n* Heavy smoking habit with ≥ 10 cig\u002Fd\n* Severe bruxism or clenching habits, present oro-facial pain\n* Insufficient ridge width\u002Fheight for the study implant\n* Defect of any alveolar wall (secondary exclusion criterion at tooth extraction)\n* ISQ \\\u003C 70 (secondary exclusion criterion for Group A at implant placement, for Group B at loading visit)","20 Years",{"count":79,"type":23},100,[26],"In this study, participants with one lower first molar that require removal and replacement using dental implants will be enrolled. The implant will be inserted 12-16 weeks after tooth extraction and restored either immediately with an artificial tooth (fixed implant crown) in 50% of the cases or 4 weeks later in the remainder 50%. Immediate and early loading will be compared and the investigators expect no difference in terms of implant success and health of the tissue around the implant.",[83],"Lower Molar Requiring Extraction","2026-06-25",{"date":86,"type":36},"2026-06-26",{"date":88,"type":36},"2021-04-01",{"date":90,"type":23},"2033-05",{"name":42,"class":43},2,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":18,"sex":19,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100308570","swiss-childhood-cancer-survivor-study-100308570","NCT03297034","Swiss Childhood Cancer Survivor Study","Swiss Childhood Cancer Survivor Study (SCCSS)","SCCSS","Inclusion Criteria:\n\n* Who were diagnosed with cancer at age \\\u003C20 years\n* Who have survived at least 5 years after cancer diagnosis\n* Who were Swiss residents when they were diagnosed, and\n* Who gave informed consent","5 Years",{"count":103,"type":23},4136,"50 Years","OBSERVATIONAL","The SCCSS is designed to investigate which long-term effects childhood cancer and its treatment have on survivors, and includes those who were under 20 years when they were diagnosed. The SCCSS explores childhood cancer survivors' quality of life, the health care received by childhood cancer survivors during follow-up care, the effects of medication, somatic and psychosocial health issues, how childhood cancer survivors take care of their own health including health behaviors, and also collects demographic details like family background, education and profession. To learn more about these topics, the investigators send questionnaires to childhood or adolescent cancer survivors. The investigators use the results to inform physicians and patients, and to improve treatment of childhood cancer and follow-up.",[108],"Childhood Cancer",[110,111,112,113],"Late effects","Childhood cancer survivors","Swiss Childhood Cancer Registry","Europe","2026-06-24",{"date":63,"type":36},{"date":117,"type":36},"2007-01-01",{"date":119,"type":23},"2050-01",{"name":42,"class":43},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":44},"100641430","international-delphi-study-to-develop-standardized-quality-criteria-and-a-rating-tool-for-liver-ceus-image-quality-assessment-100641430","NCT07656181","International Delphi Study to Develop Standardized Quality Criteria and a Rating Tool for Liver CEUS Image Quality Assessment","Delphi Study on Quality Indicators for CEUS Imaging of the Liver Using SonoVue® Contrast Agent","ICON LiverCEUS","Inclusion Criteria:\n\n* At least 6 years of active experience in ultrasound diagnostics in internal medicine, radiology, or a related clinical field\n* Independent performance of at least 5,000 ultrasound examinations Participation in structured CEUS training\n* Performance of at least 800 ultrasound examinations per year in routine clinical practice\n* Either: at least 100 independently performed CEUS examinations per year or more than 700 CEUS examinations in total\n* Regular participation in ultrasound-related meetings, case reviews, or quality assurance activities within their institution\n* Scientific involvement in CEUS, demonstrated by at least one peer-reviewed publication and\u002For active engagement in CEUS education or training\n* Signing the consent form of the participants\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria",{"count":130,"type":23},35,"This study aims to establish international consensus-based quality criteria for contrast-enhanced ultrasound (CEUS) examinations of the liver and to develop a standardized tool for assessing CEUS image quality. CEUS is an established imaging technique used in clinical practice for the characterization and assessment of focal liver lesions and other liver abnormalities. Despite its increasing use, there are currently no universally accepted or validated standards for evaluating the quality and reproducibility of CEUS examinations.\n\nThe primary objective of this project is therefore to identify robust and clinically relevant quality indicators for liver CEUS examinations through an international Delphi consensus process. The study focuses specifically on CEUS examinations performed in adult patients using the ultrasound contrast agent SonoVue®.\n\nThe project is divided into two work packages (WP). In Work Package 1 (WP1), the study team will first conduct a structured review of the available literature and discuss potential CEUS quality criteria within the research group. Based on this process, an initial catalogue of quality indicators relating to technical, procedural, and imaging characteristics relevant to liver CEUS examinations will be developed.\n\nThese proposed criteria will subsequently be evaluated through a multi-round Delphi process involving an international and interdisciplinary panel of experienced CEUS users and experts. A minimum of 20 panellists will participate across all Delphi rounds. Participants will rate their level of agreement with each proposed quality criterion using a 7-point Likert scale and may suggest additional criteria where appropriate. Newly proposed criteria supported by more than 10% of participants will be included in subsequent Delphi rounds.\n\nDuring each round, panellists will receive anonymised feedback summarising the responses of the group and will be invited to re-evaluate the relevance of the proposed criteria. This iterative process will continue for at least three rounds or until predefined consensus criteria are achieved. Consensus will be defined as at least 70% agreement with a rating of 6 or higher on the Likert scale.\n\nIn Work Package 2 (WP2), the consensus-based quality criteria identified in WP1 will be operationalised into a comprehensive and standardized rating scale for CEUS image quality assessment. Individual criteria will be grouped into broader domains and transformed into practical assessment items and prompts. The resulting rating tool will then be circulated among all Delphi panel members for final review and feedback to ensure clarity, applicability, and international usability.\n\nThe overall goal of this study is to improve standardization, quality assurance, and reproducibility in liver CEUS examinations. The developed consensus criteria and rating scale may support clinical practice, future research studies, multicentre collaborations, and educational initiatives by enabling more consistent evaluation of CEUS image quality across institutions and countries.",[133,134,135],"Contrast Enhanced Ultrasound","Ultrasonic Diagnosis","Liver",[137],"Quality Indicators of Liver CEUS","2026-06-22",{"date":84,"type":36},{"date":141,"type":23},"2026-06-01",{"date":143,"type":23},"2026-09-30",{"name":42,"class":43},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":55},"100346454","cardiac-dysfunction-in-childhood-cancer-survivors-100346454","NCT03790943","Cardiac Dysfunction in Childhood Cancer Survivors","Prospective Single Center Cohort Study for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors","Cardio-Onco","This prospective cohort study is nested within the Childhood Cancer Registry (ChCR), a national, population-based cancer registry that includes all children and adolescents in Switzerland who were diagnosed with cancer at age 0-20 years. It includes patients diagnosed with leukemia, lymphoma, central nervous system tumors, and malignant solid tumours or Langerhans cell histiocytosis. Childhood cancer survivors have survived at least 5 years from cancer diagnosis.\n\nInclusion Criteria:\n\n* Registered in the ChCR\n* Formerly treated at the Department of Pediatric Hematology\u002FOncology of one of five participating centers\n* Treated with any chemotherapy and\u002For chest radiation\n* Survived ≥ 5 years since most recent cancer diagnosis (primary cancer, relapse(s), secondary cancer) at time of examination\n* Diagnosed at age ≤ 20 years\n* ≥ 18 years of age at time of study participation\n* Resident in Switzerland\n* Written informed consent\n\nExclusion Criteria:\n\n* Study participants will be excluded if they do not meet the above mentioned inclusion criteria or refuse to participate in the study.",{"count":154,"type":23},500,"This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle tracking echocardiography as novel echocardiographic technique compared to conventional echocardiography.",[157,158,108],"Cardiac Dysfunction","Cardiovascular Diseases",[111,110,160,161,162,163],"Cardiotoxicity","Chemotherapy","Anthracyclines","Radiation","2026-05-27",{"date":166,"type":36},"2026-05-29",{"date":168,"type":36},"2018-02-13",{"date":170,"type":23},"2029-04-23",{"name":42,"class":43},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":44},"100541881","volumetric-dimensional-changes-after-surgical-pontic-site-development-procedures-with-connective-tissue-graft-or-collagen-matrix-100541881","NCT06335628","Volumetric Dimensional Changes After Surgical Pontic Site Development Procedures With Connective Tissue Graft or Collagen Matrix","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* Age ≥ 18 years\n* Willingness to sign informed consent and to participate in the study\n* Single tooth gap or extended edentulous space in the lower or posterior jaw including a pontic site with a soft tissue deficiency.\n* Tooth gap of ≥ 8 mm.\n* Presence of natural or artificial opposing dentition\n* Sufficient vertical interocclusal space of an implant restoration (7mm)\n* Bounded by natural and periodontally stable teeth\n* Treatment plan must include tooth replacement with an implant or tooth-supported fixed dental prosthesis.\n\nExclusion Criteria:\n\n* Any physical or mental disorder that would interfere with the ability to perform adequate oral hygiene or the capability of providing written informed consent and compliance with the protocol\n* Severe bruxism, clenching habits, or presence of oro-facial pain\n* Uncontrolled diabetes mellitus (HbA1c \\>7.0)\n* Clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)\n* Any active oral or systemic acute infections\n* Currently receiving chemo- or radiotherapy or a history of radiotherapy in the head and neck area\n* Severe hematologic disorders\n* Any other diseases or medications that may compromise normal wound healing\n* Pregnancy or nursing mother\n* Contraindications and limitations of the MD as described in the instructions for use: during pregnancy or lactation, children, presence of acute infection in the surgical area, patients with known sensitivity to porcine material or collagen allergies.\n* Vulnerable subjects\n* Known or suspected non-compliance\n* Drug or alcohol abuse\n* Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc.\n* Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation,\n* Enrolment of the PI, his\u002Fher family members, employees and other dependent persons",{"count":179,"type":23},38,[26],"The aim of this research project is to compare two surgical procedures to improve soft tissue volume. Both procedures have already been validated, but despite their great clinical relevance, little data exists in the literature. With this study, the investigators aim to evaluate volumetric changes of connective tissue graft versus biomaterial (membrane). In addition, further clinical measurements will be taken and patient satisfaction will be assessed.",[183,184],"Connective Tissue Graft","Volume Collagen Matrix Xenograft","2026-05-26",{"date":164,"type":36},{"date":188,"type":36},"2024-08-28",{"date":190,"type":23},"2030-04",{"name":42,"class":43},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":92},"100526033","deprescribing-inappropriate-proton-pump-inhibitors-100526033","NCT06129474","Deprescribing Inappropriate Proton Pump Inhibitors","DepRescribing inapprOpriate Proton Pump InhibiTors - the DROPIT Trial: a Cluster Randomized Controlled Trial in Primary Care Setting","DROPIT","Inclusion Criteria:\n\n1. Patient of a participating GP.\n2. Age: minimum 18 years old.\n3. Daily PPI intake for minimum 8 weeks.\n4. PPI in one of the following doses:\n\n   * minimum 40mg\u002Fday pantoprazole;\n   * minimum 40mg\u002Fday omeprazole;\n   * more than 30mg\u002Fday lansoprazole;\n   * more than 30mg\u002Fday dexlansoprazole;\n   * more than 20mg\u002Fday esomeprazole;\n   * more than 20mg\u002Fday rabeprazole.\n5. Sufficient knowledge of German language to understand the trial and follow-up according to GP assessment.\n\nExclusion Criteria:\n\n1. Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.\n2. Unable to provide informed consent.\n3. PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:\n\n   * History of bleeding ulcer.\n   * Peptic ulcer due to cause other than NSAID or H. Pylori.\n   * Barrett's oesophagus.\n   * Severe erosive reflux disease (Los Angeles grade C\u002FD).\n   * GERD with symptoms or complications (oesophageal ulcer, peptic stricture).\n   * Other indications (i.e., Zollinger-Ellison-Syndrome, PPI-sensitive eosinophilic esophagitis, chronic pancreatitis with steatorrhea refractory to enzyme replacement therapy, idiopathic pulmonary fibrosis.)\n4. Two or more of the following medications, or one of the following medications and one or more of the mentioned risk factors mentioned below.\n\nMedications (any dose):\n\n* Daily use of non-steroidal anti-inflammatory drug (NSAID) for more than 7 days.\n* Antiplatelet therapy.\n* Additional antiplatelet therapy (e.g., ticagrelor or similar).\n* Anticoagulant(s).\n* Systemic steroid(s) for more than 1 month.\n\nRisk factors:\n\n* History of gastrointestinal ulcer.\n* Age of 75 years and older.\n* Selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) use.\n* Severe concomitant disease with increased risk of GI bleeding according to the GP's assessment (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).",{"count":201,"type":23},400,[26],"The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.",[205,206,207],"Inappropriate Prescribing","Reflux Disease","Proton Pump Inhibitors",[209,210],"Deprescribing","Proton pump inhibitors","2026-05-11",{"date":213,"type":36},"2026-05-14",{"date":215,"type":36},"2024-10-01",{"date":217,"type":23},"2027-12-31",{"name":42,"class":43},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":44},"100623762","clinical-laboratory-evaluation-assessment-of-symptoms-and-recovery-in-patients-with-post-covid-19-vaccination-syndrome-100623762","NCT07400848","Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome","CLEAR","General Criteria (apply to all study parts: PROGRESS, ENDOCLOT, REAL, patients and matched healthy controls)\n\nInclusion Criteria\n\n1. Age ≥ 18 years\n2. Sufficient knowledge of German to complete study-related questionnaires and procedures\n\nExclusion Criteria\n\n1. Severe cognitive, physical impairment or psychiatric conditions impeding participation\n2. Active oncological disease or immunosuppressive\n3. Known pregnancy at the time of enrolment\n\nPROGRESS (patients only)\n\nInclusion Criteria\n\n1. Coded participation with online consent confirmation\n2. Self-reported onset of persistent symptoms temporally associated with a COVID-19 vaccination\n3. Willingness and ability to participate in the 8-month follow-up period\n\nExclusion Criteria\n\n1\\. No specific exclusion criteria for this part\n\nENDOCLOT and REAL (patients and matched healthy controls)\n\nInclusion Criteria\n\n1. Signed informed consent form\n2. For patients:\n\n   1. Receipt of at least one COVID-19 vaccination\n   2. Onset of new, otherwise unexplained symptoms within 0-14 days after vaccination\n   3. Persistence of symptoms for at least 6 months following vaccination\n   4. Selection is based on a diagnosis of ME\u002FCFS according to the Canadian Consensus Criteria (CCC) and PEM.\n\n2\\. For controls: History of COVID-19 vaccination without persistent adverse effects; age (+\u002F- 10 years), and sex match to a corresponding case\n\nExclusion Criteria (patients and matched healthy controls)\n\n1. Clinically suspected or laboratory confirmed SARS-CoV-2 infection after vaccination or temporally related to symptom onset.\n2. Concurrent pre-existing Long COVID symptoms, obtained from the patient´s history\n3. Any self-reported or uncertain history of an acute infectious event (including mild or subclinical infections) in temporal proximity to COVID-19 vaccination\n4. Known pre-existing medical conditions or ongoing medications that could plausibly explain the reported symptoms (e.g., preexisting ME\u002FCFS, POTS, fibromyalgia, small-fiberneuropathy, autoimmune disease with systemic involvement or other chronic multisystemic dysautonomia syndromes)\n5. Use of long-term, high-dose anti-inflammatory",{"count":227,"type":23},200,"Some people report persistent health problems after receiving the COVID-19 vaccine. These symptoms persist well beyond typical short-term vaccine side effects and are not attributable to any other known medical conditions. This condition is known as Post-Acute COVID-19 Vaccination Syndrome (PACVS). Symptoms can persist for months and affect several organ systems, causing issues such as fatigue, heart-related problems, neurological difficulties, and decreases in both physical ability and mental performance. PACVS shows similarities to Post-Acute COVID-19 syndrome (PACS) and myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS).\n\nThe biological processes that cause PACVS are still not fully understood. Recent research indicates that endothelial dysfunction, abnormalities in blood coagulation, and persistent inflammatory responses may contribute significantly to this process. However, it remains unclear how symptoms develop over time, which biological markers are associated with disease severity, and how these findings could support diagnosis and future treatment strategies.\n\nThe CLEAR study is an observational research project designed to address these knowledge gaps by systematically documenting symptoms over time and investigating potential biological correlates in individuals affected by PACVS. The study consists of three complementary subprojects.\n\nThe PROGRESS subproject aims to assess symptom burden, disease course, and patient-reported treatment experiences over an eight-month period using standardized questionnaires completed by participants.\n\nThe ENDOCLOT subproject investigates whether individuals with PACVS show objective signs of endothelial dysfunction, abnormalities in blood clotting, and markers of systemic inflammation. Endothelial function will be evaluated through non-invasive vascular reactivity tests (EndoPAT), microscopic examination of blood cells, standardized platelet function assessments, and standard laboratory diagnostics. It further explores the correlation between these biological parameters and clinical symptom trajectories identified in PROGRESS.\n\nThe REAL subproject examines the role of endothelial activation and the release of inflammatory signaling molecules (cytokines) in the development and persistence of PACVS.\n\nThe main hypothesis of the CLEAR study is that PACVS is associated with measurable endothelial dysfunction, inflammatory activation, and coagulation abnormalities, and that these biological changes are related to symptom severity and persistence over time. By combining longitudinal symptom assessment with biological measurements, this study aims to improve understanding of PACVS and support the development of better diagnostic and therapeutic approaches in the future.",[230,231],"Post-Acute COVID-19 Vaccination Syndrome","Postviral Fatigue",[233,234,235,236,237,238,239,240,241],"Vaccine-Related Adverse Event","Endothelial Dysfunction","Coagulation Abnormalities","Inflammation","Cytokines","Patient-Reported Outcomes","Symptom Burden","Disease Trajectory","Reactive Hyperemia Index","2026-05-04",{"date":244,"type":36},"2026-05-05",{"date":246,"type":36},"2026-03-22",{"date":248,"type":23},"2026-11-15",{"name":42,"class":43},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":19,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":277},"100324531","swiss-paediatric-airway-cohort-100324531","NCT03505216","Swiss Paediatric Airway Cohort","SPAC","Inclusion Criteria:\n\n* Children and adolescents aged 0-16 years\n* Resident in Switzerland\n* Seen in a paediatric pulmonary outpatient clinic due to respiratory problems\n* Parents and patients above age 14 must be able to sign an informed consent form\n\nExclusion Criteria:\n\nPrior diagnosis of cystic fibrosis, primary ciliary dyskinesia, severe heart disease, oncological disease, neuromuscular disease or severe disability","0 Years","16 Years",{"count":260,"type":23},6000,"The Swiss Paediatric Airway Cohort (SPAC) is a national, prospective clinical cohort of children and adolescents who visit physicians in Switzerland for recurrent wheeze, cough, and exercise- or sleep-related respiratory problems. SPAC aims to answer important questions on clinical phenotypes, prognosis, diagnosis and treatment. SPAC is part of routine care, and only clinically indicated investigations are done. The comprehensive baseline assessment includes a detailed questionnaire to families, plus test results, diagnoses and treatments from hospital records. Follow-up is via monthly questionnaires the first 12 months and thereafter annual questionnaires to families, and data from follow-up visits.\n\nCurrently, 4344 patients from 10 clinics and hospitals in Switzerland (Aarau, Basel, Bern, Chur, Horgen, Lausanne, Luzern, St. Gallen, Worb, Zurich) have been enrolled.\n\nSPAC provides real-life data on children visiting the Swiss health care system for common respiratory problems. It will provide a research platform for health services research, and for nested clinical and transitional studies.\n\nPublications and plain language summaries are listed on the study website: https:\u002F\u002Fwww.spac-study.ch\u002Fpublikationen\u002F",[263,264,265,266,267,268],"Asthma","Wheezing","Cough","Exercise Induced Bronchospasm","Inspiratory Laryngeal Obstruction","Dysfunctional Breathing","2026-04-16",{"date":271,"type":36},"2026-04-21",{"date":273,"type":36},"2017-06-06",{"date":275,"type":23},"2030-06-01",{"name":42,"class":43},12,{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":19,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":297,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":44},"100567542","effects-of-real-vs-soundless-acoustic-stimulation-during-deep-sleep-on-brain-activity-memory-and-blood-biomarkers-in-older-adults-60-85-with-mild-memory-impairment-100567542","NCT06669546","Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment","Preventing Cognitive Decline Using Portable, Non-invasive Sleep Enhancement","Inclusion Criteria:\n\n* Written informed consent\n* Age between 60 and 85 years\n* Cognitive impairment (subjective and\u002For MoCA between 23-26)\n* Native German speakers or comparably fluent\n* Normal or corrected-to-normal vision.\n* Intact hearing\n* A close cohabitant (partner\u002Fsibling) should be present to support participants in using study materials\u002Fdevices.\n\nExclusion Criteria:\n\n* Insomnia assessed by the Regensburg Insomnia Scale (RIS; Crönlein et al., 2013)\n* Restless leg syndrome assessed by questions concerning typical symptoms.\n* Sleep apnoea assessed by the Berlin Questionnaire (BQ; Netzer et al., 1999)\n* Severely irregular sleep patterns assessed by the RIS and the Pittsburgh sleep quality index (PSQI; Buysse et al., 1989)\n* Symptoms of depression (Geriatric Depression Scale (GDS; Yesavage et al., 1982) ≥ 5)\n* History of untreated severe neurological and psychiatric diseases\n* Alcohol or substance abuse\n* Use of medication acting on the central nervous system","60 Years","85 Years",{"count":288,"type":23},60,[26],"This study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality. Dementia, a leading cause of death worldwide, is often associated with disturbed sleep, particularly the loss of deep, slow-wave sleep (SWS). SWS is important for memory and clearing waste from the brain. Poor SWS can worsen memory loss and allow harmful waste to build up, which may increase the risk of dementia.\n\nThe investigators are testing whether phase-locked auditory stimulation (PLAS) can improve SWS in people at a mild stage of cognitive impairment. PLAS uses short sounds played at specific moments to strengthen slow-wave brain activity during sleep. The investigators previous laboratory based research has shown that this can improve memory and help with clearing waste from the brain. Now, the investigators want to test this in a real-world setting, over a longer period, which is unfeasible in a laboratory setting.\n\nIn this study, 60 older adults will use home-use devices that deliver either real or sham (soundless) PLAS across two different 4-week periods. Memory will be tested using engaging \"serious games.\" Before and after each experimental period, blood samples will be taken to measure dementia-related markers, and cognitive batteries will be performed. The investigators expect that PLAS will improve sleep, and that this will have a downstream effect on memory and brain clearance, potentially slowing the process of cognitive decline.\n\nIf successful, this could lead to the development of an affordable treatment that helps people maintain brain health and prevent dementia.",[292,293,294,295,296],"Cognitive Decline","Alzheimer Disease","Subjective Cognitive Decline (SCD)","Mild Cognitive Impairment (MCI)","Cognitive Impairment, Mild",[298,299,300,301,302,303,304,305,306,307,308,309,310,311],"Sleep","Dementia","Prevention","Phase-locked auditory stimulation","Blood-based biomarkers","Home","Longitudinal","Electroneurophysiology","EEG","Memory","Cognition","Serious games","Old age","Human","2026-04-02",{"date":314,"type":36},"2026-04-03",{"date":316,"type":36},"2025-02-21",{"date":318,"type":23},"2028-12",{"name":42,"class":43},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":24,"phases":329,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":44},"100631507","hyaluronic-acid-in-endodontic-microsurgery-100631507","NCT07501585","Hyaluronic Acid in Endodontic Microsurgery","Effectiveness of Using Cross-linked Hyaluronic Acid in Endodontic Microsurgery. A RCT","Inclusion Criteria:\n\n* Written informed consent\n* ≥18 years of age\n* Apical peridontitis at maxillar or mandibular first molars ≥ 12 months after non-surgical endodontical treatment\n* Full mouth plaque score (FMPS) and bleeding score (BoP) \\\u003C or 20%\n* Periapical lesion \\\u003C or 10 mm\n* Four-wall bone defect morphology\n\nExclusion Criteria:\n\n* Smokers of more than 10 cigarettes a day\n* Allergy to hyaluronic acid\n* Pregnancy or lactation\n* Uncontrolled Diabetes\n* Untreated periodontal conditions\n* Any conditions associated with poor compliance or failure to maintain good oral hygiene\n* Acute infections lesions in areas intended for surgery\n* Chemotherapy and radiotherapy treatment",{"count":328,"type":23},46,[26],"This randomized clinical trial (RCT) will evaluate the effectiveness of cross-linked hyaluronic acid as an adjunct to endodontic microsurgery in adult patients with apical periodontitis affecting maxillary or mandibular first molars. Participants previously treated with non-surgical endodontic therapy will be allocated to either endodontic microsurgery with cross-linked hyaluronic acid application (test group) or the same surgical procedure without adjunctive material (control group), with 12 months of follow-up.\n\nThe study hypothesis is that cross-linked hyaluronic acid improves soft- and hard-tissue healing, reduces postoperative inflammation and pain, and supports more stable surgical outcomes. Primary outcomes include early soft tissue healing (Early Wound Healing Score, day 4) and postoperative pain (visual analogue scale). Secondary outcomes include periapical healing assessed by blinded evaluators on periapical radiographs (Molven criteria) at 3, 6, and 12 months, and on CBCT scans (PENN 3D criteria) at 6 and 12 months, as well as cortical plate healing (RAC\u002FB index). This study aims to provide clinical evidence on the potential regenerative and anti-inflammatory benefits of cross-linked hyaluronic acid in endodontic microsurgery.",[332],"Periapical Periodontitis",[334],"Endodontic microsurgery","2026-03-24",{"date":337,"type":36},"2026-03-30",{"date":339,"type":36},"2026-02-20",{"date":341,"type":23},"2028-12-31",{"name":42,"class":43},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":24,"phases":353,"briefSummary":354,"conditions":355,"keywords":359,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":365,"locationsCount":44},"100568289","surgical-treatment-of-peri-implantitis-with-adjunctive-application-of-platelet-rich-fibrin-prf-100568289","NCT06679283","Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF)","Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF) Compared With Open Flap Debridement (OFD) Alone: A 12-month Randomised Clinical Trial","PRF","Inclusion Criteria:\n\n1. One or more peri-implant sites with PPD ≧ 5 mm combined with BOP\u002Fsuppuration and\n2. Peri-implant marginal bone loss, defined as a crater like defect ≧ 3 mm as assessed from intraoral radiographs\n3. Good oral hygiene i.e. a plaque index \\\u003C20%\n4. Written informed consent\n\nExclusion Criteria:\n\n1. History of chronic inflammatory disease\n2. Severe systemic diseases\n3. Medically confirmed diagnosis of diabetes mellitus\n4. Anti-inflammatory prescription including prednisone\n5. Smoking \\> 5 cigarettes\n6. Pregnant or lactating women\n7. \\\u003C 18 years of age",{"count":352,"type":23},40,[26],"Platelet-rich fibrin (PRF) is a second-generation platelet concentrate used for tissue and bone regeneration. PRF releases growth factors such as TGF-β, PDGF, VEGF, IGF, and FGF, which are known to promote wound healing and bone regeneration. Thus, PRF may offer a promising therapeutic approach for peri-implantitis treatment. Numerous studies have reported beneficial effects of PRF on bone regeneration, bone augmentation, soft tissue healing, and ridge preservation. In infrabony periodontal defects, PRF has shown significant improvements in pocket depth reduction, clinical attachment level (CAL) gain, and bone fill.\n\nHowever, a recent systematic review highlighted that evidence supporting PRF use in peri-implantitis remains limited, primarily due to a lack of adequately designed studies. Therefore, the aim of this project is to investigate whether PRF enhances regeneration in peri-implantitis defects. Specifically, it will assess whether surgical debridement of peri-implantitis defects-including electrochemical detoxification of implant surfaces using GalvoSurge-combined with PRF clot and membrane placement, improves treatment outcomes compared to surgical debridement and detoxification using GalvoSurge alone.\n\nFor this purpose, implants with peri-implantitis defects of comparable size will be randomly assigned to either the test or control group. After 12 months, implants will be clinically evaluated for radiographic defect fill, reduction in probing pocket depth (PPD), and bleeding on probing (BOP). The objective of this project is to verify, both radiographically and clinically, whether adjunctive PRF application enhances tissue regeneration and healing of peri-implantitis defects compared to open flap debridement (OFD) alone.",[356,357,358],"Peri-Implantitis","Bone Resorption","Platelet-Rich Fibrin",[360],"platelet rich fibrin, peri-implantitis",{"date":337,"type":36},{"date":363,"type":36},"2025-02-01",{"date":217,"type":23},{"name":42,"class":43},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":24,"phases":375,"briefSummary":376,"conditions":377,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":44},"100626575","a-novel-volume-stable-matrix-for-gingival-recession-coverage-at-teeth-100626575","NCT07437417","A Novel Volume Stable Matrix for Gingival Recession Coverage at Teeth","Assessment of Connective Tissue Graft vs. a New Collagen Matrix for Periodontal Tissue Thickening and Coverage of Single or Multiple Adjacent Gingival Recessions of Orthodontically Treated Patients. A Randomized Clinical Trial","FibroGide","Inclusion Criteria:\n\n* Written informed consent\n* Healthy patients referred to the clinic for recession coverage\n* Miller Class I, II or III facial gingival recession (GR) defect, \\>3 mm, located on the buccal of the maxillary or mandibular canine and incisor area.\n\nExclusion Criteria:\n\n* History of diseases with hypocoagulability, instable diabetes mellitus, post-irradiation in the head and neck area, infectious diseases or heart diseases that need prophylactic antibiosis before dental treatments or a medication with effect on the gingiva: Ciclosporin A, compounds of Phenytoin, calcium channel blockers, pregnant or breastfeeding patients",{"count":288,"type":23},[26],"Periodontal health and preservation of the dentition without tooth loss are important quality of life components and should be safeguarded in order to provide optimal function and esthetics. Optimal treatment of gingiva recessions is likely to allow for more efficient use of healthcare resources and reduced costs long-term. It is evident that the prevalence in gingival recession is high and its consequences on the aging population constitute an important healthcare issue that requires further attention. The standard therapy of gingival recession encompasses a coronally advanced flap or coronally advanced tunnel flap and a connective tissue graft from the palate. Harvesting of the palatal graft involves a second surgical site and increased morbidity for the patients.This project aims to compare the connective tissue graft against a novel volume stable collagen matrix.\n\nPatients will be treated according to standard protocols of the Department of Periodontology. In the test group patient will undergo tissue thickening with a collagen matrix and the modified coronally advanced tunnel technique. The control group will undergo the standard protocol using a connective tissue graft from the palate along with the modified coronally advanced tunnel technique. No study specific risks do exist.",[378,379],"Gingival Recession","Connective Tissue Defect",[381,382,383],"Connective tissue graft","Collagen Matrix","single and multiple gingival recessions","2026-02-23",{"date":386,"type":36},"2026-02-27",{"date":388,"type":36},"2025-09-01",{"date":390,"type":23},"2030-08-01",{"name":42,"class":43},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":19,"minAge":400,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":24,"phases":404,"briefSummary":405,"conditions":406,"keywords":410,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":44},"100598460","web-based-alcohol--or-cocaine-specific-inhibition-training-in-adolescents-and-young-adults-with-substance-use-disorder-100598460","NCT07071779","Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder","Web-based Alcohol- or Cocaine Specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder","WAIT-AYA","Inclusion Criteria:\n\n* Age 14 - 35 years\n* Alcohol use disorder identification test (AUDIT) ≥ 7 or Drug Use Identification Test (DUDIT) ≥ 8\n* Currently undergoing outpatient treatment or online counselling in one of 7 specialized treatment settings\n* Sufficient German language skills\n* Informed Consent as documented by signature\n* Owner of a smartphone with internet access\n\nExclusion Criteria:\n\n* Other severe substance use (except nicotine and cannabis) determined by the cut-off value ≥ 25 in the drug use disorder identification test (DUDIT)\n* Current medical conditions excluding participation\n* Inability to read and understand the participant's information\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons\n\nAdditional exclusion criteria for Electroencephalography (EEG)-substudy:\n\n* Current medication affecting EEG (e.g., benzodiazepines)\n* Other severe substance use determined by the cut-off value ≥ 25 in the DUDIT (except nicotine)\n* History of epilepsy\n* Cochlea implant","14 Years","35 Years",{"count":403,"type":23},210,[26],"Substance misuse is one of the most common risk factors for health problems and premature death among adolescents and young adults worldwide. Although there are effective treatments for substance use disorder (SUD), there is still a need to further improve their effectiveness and make them easier to access. Early research suggests that substance-specific inhibition training, when used in addition to specialized treatment, can improve treatment outcomes. This training aims to strengthen inhibition specifically in situations with substance-related cues. The goal of this project is to offer this training for the first time in the form of a smartphone app, which is expected to increase the availability of the training. The main aim of the study is to evaluate whether this new app-based cognitive training is feasible as an add-on to the treatment of SUD in adolescents and young adults. In addition, the study will gather preliminary insights into whether the training affects drinking behavior and related brain processes. The project will be conducted as a double-blind, clinical pilot study. A total of 210 adolescents and young adults between 14 and 35 years old will be recruited from five specialized treatment centers. After the first study visit, participants will be randomly assigned to one of two groups: (1) an intervention group receiving the alcohol-specific inhibition training or (2) a control group receiving a similar alcohol-nonspecific inhibition training. During their participation, all participants will complete six short training sessions with the app. About one month later, they will complete six additional booster training sessions. This research may help develop effective, easily accessible tools to support young people with substance use disorder.",[407,408,409],"Alcohol Use Disorder (AUD)","Cocaine Use Disorder (CUD)","Substance Use Disorder (SUD)",[411,412,413,414,408,409,415,416],"Alcohol use disorder","Alcohol-specific inhibition training","Cognitive bias modification","Feasibility pilot randomized controlled trial","Cocaine-specific inhibition training","Substance-specific inhibition training","2026-02-16",{"date":419,"type":36},"2026-02-18",{"date":421,"type":36},"2025-07-23",{"date":423,"type":23},"2026-08",{"name":42,"class":43},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":24,"phases":435,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":44},"100523746","clinical-performance-of-dual-cantilevered-single-implant-bridge-100523746","NCT06099717","Clinical Performance of Dual-cantilevered Single-implant Bridge","Clinical Performance of a Novel Implant-supported Fixed Dental Prostheses (iFDP): the Dual-cantilevered Single-implant Bridge (T-bridge)","T-bridge","Inclusion Criteria:\n\n* Age ≥ 20 years\n* Willingness to sign an informed consent and participate in the study\n* Three missing adjacent teeth in the posterior site.\n* Tooth gap of 21-24 mm.\n* Presence of natural or artificial opposing dentition\n* Sufficient vertical interocclusal space of an implant restoration (7mm)\n* Sufficient ridge height to place an implant of 10mm in length\n* Sufficient ridge width for the placement of a 4.1mm diameter implant. Simultaneous GBR to achieve a width of 6.5mm will be included.\n\nExclusion Criteria:\n\n* Any physical or mental disorder that would interfere with the ability to perform adequate oral hygiene or the capability of providing written informed consent and compliance with the protocol\n* Any disorder that would interfere with wound healing or represent a contraindication for implant surgery, such as but not limited to uncontrolled diabetes or conditions resulting in or requiring immunosuppression, radiation, chemotherapy, frequent use of antibiotics or antiresorptive medication such as bisphosphonates.\n* Pregnancy or lactation\n* Heavy smoking habit with ≥ 10 cig\u002Fd\n* Severe bruxism or clenching habits, presence of oro-facial pain\n* Insufficient ridge width\u002Fheight for the study implant",{"count":434,"type":23},50,[26],"The study aims to evaluate the clinical performance (implant and prosthetic survival\u002F success rates) of a novel implant-supported fixed dental prosthesis design: the dual-cantilevered single implant bridge (T-Bridge) made out of monolithic zirconia bonded to a titanium base abutment (Variobase abutments)",[438],"Dental Implant Failed",[440],"Dental implant",{"date":419,"type":36},{"date":443,"type":36},"2024-06-30",{"date":445,"type":23},"2026-10",{"name":42,"class":43},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":456,"briefSummary":457,"conditions":458,"keywords":464,"overallStatus":467,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":44},"100578042","the-inspire-study-investigation-of-swiss-physicians-inner-life-resilience-and-emotions-100578042","NCT06806150","The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions","INSPIRE","Inclusion Criteria:\n\n1. Be a practicing physician in Switzerland\n2. Working at least 40% in a clinical capacity\n3. Be willing and able to provide informed consent\n4. Expecting to be professionally active until 2028\n\nExclusion Criteria:\n\n1. Retired physician or physician seeking retirement within 3 years from first participation in the study\n2. Physician unable to participate in one of the study languages: English, German, or French",{"count":455,"type":23},450,[26],"The goal of this clinical trial, nested within an observational cohort study, is to evaluate whether two positive psychology web-based interventions can reduce emotional exhaustion and improve overall well-being in practicing physicians in Switzerland. The main questions it aims to answer are:\n\nDoes participation in positive psychology interventions reduce emotional exhaustion at three months post-intervention? How do these interventions impact physician wellness, job satisfaction, comfort with end-of-life communication and other aspects of physicians' emotional well-being?\n\nResearchers will compare the effects of two intervention arms (general reflection vs. work-specific reflection) to a control group to determine whether focusing on work-specific aspects leads to greater improvements in emotional exhaustion and job-related outcomes.\n\nParticipants will:\n\n* Complete an 8-day intervention consisting of positive psychology activities delivered online.\n* Complete baseline and follow-up assessments over the study period",[459,460,461,462,463],"Burnout, Professional","Emotional Exhaustion","Emotions","Wellness, Psychological","Satisfaction, Personal",[465,466],"Psychological resilience","Positive Psychology","NOT_YET_RECRUITING","2026-02-11",{"date":470,"type":36},"2026-02-13",{"date":472,"type":23},"2026-04-15",{"date":474,"type":23},"2027-08-15",{"name":42,"class":43},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":19,"minAge":257,"maxAge":4,"enrollmentInfo":483,"targetDuration":485,"studyType":105,"phases":4,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":277},"100438714","swiss-cerebral-palsy-registry-100438714","NCT04992871","Swiss Cerebral Palsy Registry","Swiss-CP-Reg","Inclusion Criteria:\n\n* Who were diagnosed with CP, confirmation of the diagnosis at the age of 5 years is required\n* Who are born, treated for CP or living in Switzerland, and\n* Who gave informed consent\n\nExclusion Criteria:\n\n* Pure muscular hypotonia\n* Neurometabolic diseases (e.g. neuronal storage diseases, leukodystrophies)\n* Other progressive neurological diseases (e.g. spinocerebellar ataxias, hereditary spastic paraplegia, Rett syndrome, epileptic encephalopathy)",{"count":484,"type":23},15000,"80 Years","The Swiss-CP-Reg is a national patient registry that collects information on diagnosis, symptoms, treatment and follow-up of patients with cerebral palsy (CP) in Switzerland. It was first implemented in 2017 in the paediatric clinics in Basel, Bellinzona, Bern, Geneva, Lausanne, St. Gallen and Zurich. It is currently extended to all Swiss clinics and medical practices and adults will be invited to join the register in the coming years. The registry provides data for national and international monitoring and research. It supports research on CP in Switzerland and the exchange of knowledge between clinicians, researchers and therapists, with the goal to improve the treatment of children and adults with CP and optimizing their health and quality of life.",[488],"Cerebral Palsy",{"date":470,"type":36},{"date":491,"type":36},"2017-06-19",{"date":493,"type":23},"2071-01",{"name":42,"class":43},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":18,"sex":19,"minAge":503,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":24,"phases":506,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":44},"100623822","in-vehicle-real-time-cannabis-influenced-driving-detection-100623822","NCT07401628","In-Vehicle Real-Time Cannabis Influenced Driving Detection","Randomised, Controlled, Interventional Single-center Study for the Design and Evaluation of an In-vehicle Real-time System for Detecting Cannabis-impaired Driving (CID)","REVELIO","Inclusion Criteria:\n\n* Informed consent as documented by signature\n* Recreational cannabis-consumption (more than once per month)\n* In possession of a definite Swiss or European Union (EU) driving license\n* At least 21 years old\n* Active, regular driving a car in the last 6 months\n* Must be in good health condition\n* No special equipment needed when driving (special seats, levers, etc.)\n* Fluent in (Swiss) German and no speech impairment\n\nExclusion Criteria:\n\n* Health concerns where cannabis consumption is contra-indicated (such as: high blood pressure, psychiatric problems (e.g. psychosis, depression, attention-deficit conditions, etc.)\n* Cannabis-abstinence or excessive consumption, , assessed using the Cannabis Use Disorders Identification Test-Revised (CUDIT-R)\n* For women: pregnancy or breastfeeding or if intention to become pregnant during study period (time between telephone screening and study day (visit 2)\n* Alcohol misuse or excessive alcohol consumption habits\u002Frisky drinking behaviour, assessed using the Alcohol Use Disorders Identification Test (AUDIT) and\u002For phosphatidylethanol (PEth) in capillary blood \\> 200 ng\u002FmL at first visit\n* If breath alcohol test is positive at Visit 1 or Visit 2 (study day)\n* Consumption of drugs of abuse (others than cannabis) within 4 weeks before the study\n* Consumption of medications \u002F pharmaceutical drugs which interfere with driving ability\n* Inability to follow the procedures of the study, e.g., due to language","21 Years",{"count":505,"type":23},45,[26],"The goal of this clinical trial is to evaluate whether in-vehicle sensor data can be used to detect cannabis-impaired driving in healthy adult recreational cannabis users.\n\nThe study aims to assess whether changes in vehicle, driver, and physiological sensor data can distinguish sober driving from cannabis-impaired driving, and how driving performance changes from baseline to approximately 1 to 6 hours after controlled cannabis consumption.\n\nResearchers will compare driving behavior and in-vehicle sensor data from participants who receive controlled cannabis administration with data from a randomized reference group without cannabis exposure, to determine whether cannabis-related impairment driving can be identified on the basis of machine learning.\n\nParticipants will complete screening and baseline assessments and drive an instrumented vehicle on a closed test track under sober conditions. Participants assigned to the experimental arm will receive controlled cannabis administration, while participants in the reference arm will receive no intervention. All participants will perform repeated standardized driving sessions over several hours and complete traffic-medical, traffic-psychological, and in-vehicle pre-driving tests. Biological samples and in-vehicle sensor data will be collected throughout the study.",[509,510],"Driving Under the Influence","Cannabis-impaired Driving","2026-02-03",{"date":513,"type":36},"2026-02-10",{"date":515,"type":36},"2026-01-05",{"date":517,"type":23},"2026-06-19",{"name":42,"class":43},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":53,"enrollmentInfo":527,"targetDuration":4,"studyType":24,"phases":529,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":547},"100564546","phase-3-gipglp-1ra-as-adjunctive-to-automated-insulin-delivery-in-adults-with-type-1-diabetes-100564546","NCT06630585","GIP\u002FGLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes","GIP\u002FGLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes: A Prospective, Randomized, Clinical Study - The AID-JUNCT Trial","AID-JUNCT","Inclusion Criteria:\n\n1. Participants with diagnosed T1D for at least 12 months.\n2. Aged between 18 to 65 years old (inclusive).\n3. Currently on AID therapy for at least three months.\n4. HbA1C higher or equal to 6.5% and less or equal to 10%.\n5. BMI ≥23 kg\u002Fm2.\n6. Willing to use once-weekly tirzepatide for at least 16 weeks (including four weeks of up-titration and 12 weeks of treatment)\n7. Willing to wear a Dexcom G7 Sensor and share devices (AID) data uploads.\n8. Willingness not to start any new non-insulin glucose-lowering agent during the trial (including metformin\u002Fbiguanides, pramlintide, DPP-4 inhibitors, sodium-glucose cotransporter 2 inhibitors \\[SGLT2 inhibitors\\], and nutraceuticals).\n9. A stable weight (± 5%) in the last 90 days or more before the screening and agree to not initiate a diet and\u002For exercise program during the study to reduce body weight other than the lifestyle and dietary measures for diabetes treatment.\n10. Females with childbearing potential and males (if apply) must be willing to use reliable contraceptive methods (for the contraceptives study guidelines. See Annex 7 of the protocol)\n11. An understanding and willingness to follow the protocol and signed informed consent.\n\nExclusion Criteria:\n\n1. History of diabetic ketoacidosis requiring hospitalization in the past six months.\n2. History of severe hypoglycemic event (Level 3, defined as seizure or loss of consciousness) in the past six months.\n3. Uncontrolled Diabetic retinopathy or maculopathy\n4. Severe gastroparesis.\n5. Less than 12 months of insulin treatment.\n6. Estimated glomerular filtration rate (eGFR) lab value below 30 mL\u002Fmin\u002F1.73 m2 by the CKD-EPI formula(99).\n7. Pregnancy or intention to become pregnant during the trial (See annex 7).\n8. Currently breastfeeding or planning to breastfeed.\n9. Currently uncontrolled seizure disorder.\n10. History of allergy to GIP\u002FGLP-1RAs or its excipients.\n11. Personal or family history of multiple endocrine neoplasia type 2 (MEN-2) or medullary thyroid carcinoma.\n12. Screening calcitonin above or equal to 35 ng\u002FL.\n13. Planned any surgery during the study duration.\n14. Have uncontrolled hypertension (systolic BP above or equal to 160 mmHg and\u002For diastolic BP above or equal to 100 mmHg). If a participant is on anti-hypertensive therapies, doses must be stable for 30 days before screening. For participants with uncontrolled hypertension at the screening visit, antihypertensive medication may be started or adjusted.\n15. Personal history of one of the following cardiovascular conditions (within two months before the screening): acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF).\n16. Conditions that may increase the risk of induced hypoglycemia, such as CHF with NYHA Functional Classification III or IV or adrenal insufficiency.\n17. Have a history of documented human immunodeficiency virus (HIV) infection.\n18. Have an uncontrolled cardiac arrhythmia based on an electrocardiogram (ECG) at the screening time and the investigator's discretion.\n19. Cystic fibrosis.\n20. Patient with a history of gastric bypass (bariatric) surgery, sleeve gastrectomy, or restrictive bariatric surgery, such as Lap-Band® or gastric banding.\n21. Uncontrolled thyroid disease as judged by the investigator\n22. Serum triglycerides higher than 5.7 mmol\u002FL (500 mg\u002FdL) at the screening. If a participant is on lipid-lowering therapies, doses must be stable for 30 days before screening.\n23. Personal history of acute or chronic pancreatitis. A participant with a history of acute pancreatitis caused by gallstones may be included in the study if the participant has had a cholecystectomy to resolve the problem.\n24. Acute or chronic hepatitis other than MASLD.\n25. Have a history of symptomatic gallbladder disease within the past two years (unless the participant has had a cholecystectomy to resolve the problem).\n26. History of malignancy requiring chemotherapy, surgery, or radiation (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) in the previous five years.\n27. Active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (such as known drug or alcohol abuse, diagnosed eating disorder, or any other uncontrolled psychiatric disorder) that, in the investigator's opinion, may preclude the participant from following and completing the protocol.\n28. Treatment with non-insulin glucose-lowering agents other than metformin (on a stable dose 30 days before the study)\n29. Weight loss medications in the past three months.\n30. Participants who are anticipated to receive, are receiving, or have received within three months before the screening (more than two weeks and more or equal to 10mg prednisolone-equivalent) chronic systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, single intraarticular injection, or inhaled preparations).\n31. Have current treatment with (or history of, within three months before screening) medications that may significantly affect glucose metabolism.\n32. Use of investigational drugs within five half-lives before screening.\n33. Participation in another study with an investigational drug within the 30 days preceding and during the present study.\n34. Current enrollment in another clinical trial unless approved by the investigator of both studies and if the clinical trial is a non-interventional registry trial.\n35. Have evidence of a significant active, uncontrolled medical condition or a history of any medical problem capable of constituting a risk when using the study devices or interfering with following study procedures or the interpretation of data, as judged by the study physician at screening.\n36. The enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons.",{"count":528,"type":23},42,[530],"PHASE3","Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \\~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1RAs have emerged as promising add-ons to insulin in T1D.\n\nThis application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP\u002FGLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.",[533],"Type 1 Diabetes (T1D)",[535,536,537,538],"Type 1 diabetes","Adjuvant therapy","Incretins","GIP\u002FGLP-1RA","2026-01-22",{"date":541,"type":36},"2026-01-26",{"date":543,"type":36},"2025-02-14",{"date":545,"type":23},"2026-06",{"name":42,"class":43},3,{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":24,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":44},"100536352","differences-between-suicide-attempters-and-suicide-ideators-influence-of-the-brief-therapy-attempted-suicide-short-intervention-program-assip-on-neuropsychological-correlates-and-psychological-process-factors---project-2-100536352","NCT06263712","Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy Attempted Suicide Short Intervention Program (ASSIP) on Neuropsychological Correlates and Psychological Process Factors - Project 2","Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy ASSIP on Neuropsychological Correlates and Psychological Process Factors (NePsyASSIP HT) - Project 2","NePsyAssip HT","Inclusion Criteria for Project 2:\n\nSubjects fulfilling the following inclusion criteria are eligible for the study:\n\n* Informed consent as documented by signature\n* Age ≥ 18 years\n* At least one previous suicide attempt\n* Willingness to attend the ASSIP brief therapy\n* Owns a smartphone\n\nExclusion Criteria for Project 2:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the subject:\n\n* Serious cognitive impairment\n* Any psychotic disorder\n* Any current medication, which substantially impairs the attention span, reaction, rate or any other relevant cognitive functions\n* Inability to follow the procedures of the study (e.g., insufficient mastery of the German language, previous enrolment into the current study)",{"count":557,"type":23},156,[26],"The present study consists of 3 projects in total and aims to investigate the (neuro-) psychological patterns from suicidal ideation to suicidal behavior as well as the effects and feasibility of ASSIP Home Treatment.\n\nThe overall aim of project 2 is to investigate how the (neuro-) psychological patterns are modulated by the Attempted Suicide Short Intervention Program (ASSIP). Therefore, suicide attempters participating in this project 2 will be randomly assigned to either the intervention group ASSIP or a standard care plus resource interview (STAR) group. The ASSIP and STAR interventions take place at the University Hospital of Psychiatry and Psychotherapy Bern (Switzerland).\n\nAt the end of the assessment in project 1 participants who reported a history of past suicide attempt (SUAT) will be informed about project 2.\n\nOnly if participants agreed to take part in project 2 and have signed the informed consent, they are randomized into two conditions: The ASSIP intervention (ASSIP) versus standard of care plus resource interview (STAR). Participants of both groups will be assessed again 4 weeks and 12 months after their first baseline assessment of project 1.",[561,562,563,564,565,566,567],"Inhibitory Control","Self Efficacy","Suicide Ideation","Suicide, Attempted","Locus of Control","Process Factors","Movement Synchrony","2026-01-19",{"date":539,"type":36},{"date":571,"type":36},"2024-03-25",{"date":573,"type":23},"2026-12",{"name":42,"class":43},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":554,"eligibilityCriteria":581,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":44},"100535164","neuropsychological-patterns-of-suicide-ideators-and-suicide-attempters-100535164","NCT06248268","Neuropsychological Patterns of Suicide Ideators and Suicide Attempters","Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy ASSIP on Neuropsychological Correlates and Psychological Process Factors (NePsyASSIP HT) - Project 1","Inclusion Criteria:\n\nSubjects fulfilling the following inclusion criteria are eligible for the study:\n\n* Informed consent as documented by signature\n* Age ≥ 18 years\n\nAdditional inclusion criterion for the SUAT group in project 1:\n\n• At least one previous suicide attempt\n\nAdditional inclusion criterion for the SUID group in project 1:\n\n• Suicidal ideation\n\nAdditional inclusion criterion for the CLIN group in project 1:\n\n• Current psychiatric disorder treated on an inpatient, day-care or outpatient basis For the HLTH group, no further inclusion criteria are formulated.\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria leads to exclusion of the subject:\n\n* Serious cognitive impairment\n* Any current psychotic disorder\n* Any current medication, which substantially impairs the attention span, reaction rate or any other relevant cognitive functions\n* Inability to follow the procedures of the study (e.g., insufficient mastery of the German language, previous enrolment into the current study)\n\nAdditional exclusion criterion for the SUID group:\n\n• Previous suicidal behavior\n\nAdditional exclusion criteria for the CLIN and HLTH groups:\n\n* Previous suicidal behavior\n* Suicidal ideation\n\nAdditional exclusion criterion for the HLTH group:\n\n• Current psychiatric disorder treated on an inpatient, day-care or outpatient basis",{"count":583,"type":23},180,"The present study consists of 3 projects in total and aims to investigate the (neuro-) psychological patterns from suicidal ideation to suicidal behavior as well as the effects and feasibility of ASSIP Home Treatment.\n\nThe overall aim of project 1 is to determine (neuro-) psychological differences between suicide attempters, suicide ideators, a clinical control group, and healthy controls. Study participants in project 1 will participate in a one-time (neuro-) psychological assessment.\n\nProject 1 of this study is an observational cross-sectional study with four groups that will be conducted at the University Hospital of Psychiatry and Psychotherapy Bern (Switzerland): Patients with at least one suicide attempt in their past (SUAT), patients with suicidal ideation (SUID), patients from the same clinical cohort, without neither suicidal behavior or ideation (CLIN) and the healthy group (HLTH). The cohorts to be examined (SUAT \\& SUID) will be compared to the two control groups (CLIN \\& HLTH). Only people who have signed the informed consent and meet the eligibility criteria can participate in this study.",[561,565,562,564,586,587],"Suicidal Ideation","Attention","2026-01-15",{"date":590,"type":36},"2026-01-16",{"date":592,"type":36},"2024-08-08",{"date":594,"type":23},"2026-12-31",{"name":42,"class":43},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":19,"minAge":257,"maxAge":4,"enrollmentInfo":604,"targetDuration":485,"studyType":105,"phases":4,"briefSummary":606,"conditions":607,"keywords":613,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":625},"100447167","swiss-registry-for-neuromuscular-disorders-100447167","NCT05102916","Swiss Registry for Neuromuscular Disorders","Swiss Registry for Neuromuscular Disorders (Swiss-Reg-NMD)","Swiss-Reg-NMD","Inclusion Criteria:\n\n* Children, adolescents and adults diagnosed with a NMD\n* Who are living or treated for a NMD in Switzerland, and\n* Who gave informed consent\n\nExclusion Criteria:\n\n* None if diagnosis is confirmed, whenever possible, by genetic testing, or at least by biopsy and\u002For electroneuromyography, according to international standards for the diagnosis of the given NMD.",{"count":605,"type":23},2000,"The Swiss Patient Registry for DMD\u002FBMD and SMA was launched in 2008 in order to give Swiss patients access to new therapies. It was founded with the financial support of several patient organizations and research foundations. Since 2008, children, adolescents and adults with DMD, BMD and SMA are registered with the help of all major muscle centers in Switzerland. After nearly ten years of activity, the Swiss Patient Registry for DMD\u002FBMD and SMA implemented several adaptations in 2018 to meet current and future expectations of patient's organizations, health authorities and research organizations.",[608,609,610,611,612],"SMA","DMD","BMD","IMD","Congenital Muscular Dystrophy",[609,610,611,608,614,615,616,617],"LAMA2","COL-6","CMD","NMD","2026-01-13",{"date":588,"type":36},{"date":621,"type":36},"2018-06-20",{"date":623,"type":23},"2071-01-01",{"name":42,"class":43},19,{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":104,"enrollmentInfo":633,"targetDuration":4,"studyType":24,"phases":634,"briefSummary":635,"conditions":636,"keywords":638,"overallStatus":467,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":44},"100279577","systematically-assessing-effects-of-colored-light-on-humans-with-a-multi-modal-approach-substudy-5-of-7-100279577","NCT02919189","Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7)","Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach","Inclusion Criteria:\n\n* Normal color vision\n* Right handed\n* Written informed consent\n\nExclusion Criteria:\n\n* Smoking\n* Any kind of diagnosed sleep disorder or neurological or psychiatric disorder in the last 3 months\n* Acute severe traumas\n* Chronic diseases with the necessity for medication\n* Use of recreational drugs\n* Regular intake of medication that would affect the outcome measures\n* Regular excessive alcohol use (\\> 18 standard units \u002F week)\n* Transmeridian travel in the last month (crossed \\> 1 time zone border)\n* Night shift word during the last month",{"count":434,"type":23},[26],"NOTE: This is the fifth of in total 7 sub-studies related to the Ethics Committee of the Canton of Bern Ref. No. KEK-BE 2016-00674. This sub-study includes 50 participants and 8 arms, in total 350 participants will be assessed in all 7 sub-studies.\n\nGeneral study information: This is a randomized, cross-over, quantitative study, which investigates physiological variables, mood, and affect of healthy participants in response to colored light exposure. The Participants take part in 5-8 arms and are exposed to colored light only, or are additionally asked to solve cognitive tasks during the colored light exposure. Primary aim is to measure the change in several physiological variables, mood, and affect during colored light exposure of 15 or 45 minutes. The risk for the participants is negligible and comparable to the risk during daily life.",[637],"Exposure to Man-made Visible Light",[639,640,641,642,643,644,645,646,647,648,649,650],"cerebral oxygen metabolism","functional near-infrared spectroscopy","partial pressure of carbon dioxide","heart rate variability","blood pressure","affect","mood","respiration","systematic randomized cross-over study","systemic physiology","electro-dermal activity","pulse-respiratory quotient","2026-01-12",{"date":653,"type":36},"2026-01-14",{"date":655,"type":23},"2027-12-01",{"date":657,"type":23},"2029-07-31",{"name":42,"class":43},{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":104,"enrollmentInfo":664,"targetDuration":4,"studyType":24,"phases":665,"briefSummary":666,"conditions":667,"keywords":668,"overallStatus":467,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":669,"startDateStruct":670,"completionDateStruct":671,"leadSponsor":672,"locationsCount":44},"100279575","systematically-assessing-effects-of-colored-light-on-humans-with-a-multi-modal-approach-substudy-6-of-7-100279575","NCT02919163","Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7)",{"count":434,"type":23},[26],"NOTE: This is the sixth of in total 7 sub-studies related to the Ethics Committee of the Canton of Bern Ref. No. KEK-BE 2016-00674. This sub-study includes 50 participants and 8 arms, in total 350 participants will be assessed in all 7 sub-studies.\n\nGeneral study information: This is a randomized, cross-over, quantitative study, which investigates physiological variables, mood, and affect of healthy participants in response to colored light exposure. The Participants take part in 5-8 arms and are exposed to colored light only, or are additionally asked to solve cognitive tasks during the colored light exposure. Primary aim is to measure the change in several physiological variables, mood, and affect during colored light exposure of 15 or 45 minutes. The risk for the participants is negligible and comparable to the risk during daily life.",[637],[639,640,641,642,643,644,645,646,647,648,649,650],{"date":653,"type":36},{"date":655,"type":23},{"date":657,"type":23},{"name":42,"class":43},""]